Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD
Study
Inclusion/Exclusion
Description Intervention
treated patients
Criteria/Population
RUPP, 2005 Assessments: Race/ethnicity, RCT
(continued) Intelligence testing, Lab population, n (%):
tests, ECGS, at entry White: 44 (69.8)
into the extension phase Black: 6 (9.5)
and prior to the Hispanic: 3 (4.8)
discontinuation phase Asian or Pacific islander: 4
(6.3)
VABS maladaptive Other: 6 (9.5)
behavior at entry to the SES:
open label extension Education of parent or
phase
primary caregiver, n (%):
Vital signs, height, Less than high school: 1
weight at each visit (1.6)
Neurological side effects High school: 13 (20.6)
done by Simpson – Trade or Technical school:
Angus Rating scale and 4 (6.3)
AIMS.
At least some college: 35
medical history, physical (55.6)
examination Clinician Advanced degree: 10
rated CGI and monthly (15.9)
scores on the parent Annual household
rated subscales of ABC- income, n (%):
C
< $20,000: 6 (9.5)
weekly assessment in $20,001-$40,000: 17 (27)
the discontinuation $40,001-$60,000: 15
phase
(23.8)
Groups:
> $60,000: 23 (36.5)
Open label extension Diagnostic approach:
phase:
In Study
G1: risperidone Diagnostic tool/method:
Discontinuation phase: Diagnosis corroborated by
G1: risperidone ADI-R, administered by a
G2: placebo
clinician with special
training and systematic
Co-interventions held review to ensure reliability
stable during
Diagnostic category:
treatment:
See inclusion criteria
NR
Other characteristics, n
Concomitant therapies: (%):
NR
Educational placement of
N at start of extension child: (n=63)
phase:
Regular class: 4 (6.3)
G1: 63*
Special education
N at end of extension program:
phase:
47 (74.6)
G1: 51
Special school: 11 (17.5)
N at enrollment of Residential school: 0
discontinuation phase: Other: 1 (1.6)
Total: 38
Current anticonvulsant
N at end of
treatment: n (%): 1/63
RUPP, 2005
discontinuation phase: (1.6)
G1: 16
G2: 16
Previous medication
(continued)
(n=63):
Medication naïve: 11
C-320
Baseline
Measures Outcomes
Anxiety,
Difficulty falling asleep,
Fever, Skin irritation,
Vomiting: 4.8
Accidental injury ,
Constipation,
Drowsiness/sedation,
Enuresis, Headache,
Hypersalivation,
Sore throat: 3.2
Depression, Diarrhea,
Difficulty urinating,
Dyskinesia,Earache ,
Restlessness/agitation ,
Sinus condition,
Stomach/abdominal
discomfort,
Tiredness/fatigue,
Tremor, Weight gain,
Muscle rigidity, Other:
1.6
Modifiers:
No predictors of relapse
were identified